logo

For the Inventor, By the Inventor

Princeton, NJ, United States of America

Arthur F Wagner

USPTO Granted Patents = 14

Average Co-Inventor Count = 2.6

ph-index = 9

Forward Citations = 222(Granted Patents)


Company Filing History:

goldMedal14 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1976-1991

Loading Chart...
14 patents (USPTO):Explore Patents
1. 4994464 - Piperazinylpyrimidines as .beta.-adrenergic receptor blockers (1991-02-19),
2. 4980350 - Piperazinylalkylpyrimidines as hypoglycemic agents (1990-12-25),
3. 4889856 - 7,8-dihydro-4-(1-pierazinyl)-6H-thiopyrano-[3,2-d] pyrimidines as (1989-12-26),
4. 4801710 - Regioselective synthesis of 9-substituted purine acyclonucleoside (1989-01-31),
5. 4217429 - Poly-[(methylimino)trimethylene] (1980-08-12),
6. 4206295 - Process of preparing poly[{alkyl-(3-ammoniopropyl)iminio}trimethylene (1980-06-03),
7. 4205064 - Bile acid sequestering composition containing (1980-05-27),
8. 4185088 - Non-adhesive ionene quaternary polymer compositions useful as bile acid (1980-01-22),
9. 4161581 - Poly-[(dialkyl and hydroxy-dialkyl-imino)ethylene halides] and process (1979-07-17),
10. 4098726 - Poly[{alkyl-(3-ammoniopropyl)iminio}trimethylene dihalides] and process (1978-07-04),
11. 4071478 - Controlled partially cross-linked 3,3-ionenes (1978-01-31),
12. 4016209 - 3-[N'-(3-Halopropyl)-N-'-methylamino]-N,N,N-trimethyl-1-propanaminium (1977-04-05),
13. 4007190 - 3,6-Bis(2-piperidinyl)-2,5-piperazinedione compounds (1977-02-08),
14. 3971736 - Cathepsin in D inhibitors (1976-07-27),

Title: The Innovations of Arthur F. Wagner

Introduction

Arthur F. Wagner is a notable inventor based in Princeton, NJ (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of 14 patents to his name, he has made remarkable advancements in the development of therapeutic agents.

Latest Patents

Among his latest patents, Wagner has developed piperazinylpyrimidines as β-adrenergic receptor blockers. These compounds exhibit pronounced β-adrenergic blocking properties and are particularly useful in treating elevated intraocular pressure and glaucoma. Additionally, he has introduced piperazinylalkylpyrimidines as novel hypoglycemic agents, showcasing his innovative approach to addressing critical health issues.

Career Highlights

Wagner is currently associated with Merck & Company, Inc., where he continues to push the boundaries of pharmaceutical research. His work has not only contributed to the scientific community but has also had a profound impact on patient care and treatment options.

Collaborations

Throughout his career, Wagner has collaborated with esteemed colleagues such as Tsung-Ying Shen and Nathaniel Grier. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Arthur F. Wagner's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a leading inventor. His work continues to influence the development of important therapeutic agents that address significant health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…